Nanoviricides

Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.

xr:d:DAFl_HSvCpE:2,j:6755793051000407071,t:23061612

News

Intraday Update

Markets

Movers

Trading Ideas

ALUR

APLD

ASNS

BILI

DMTK

ESPR

FEMY

GRDI

HIMX

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HROW

IBRX

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

KAVL

LOBO

LRHC

MBIO

MGOL

MOLN

NKLA

NLSP

NNVC

NYAX

OCUL

PACK

PRST

RELI

SLNH

SMCI

SONN

SRFM

SVMH

TBLT

Tempest Therapeutics, Inc. - Common Stock

TPST

TRVN

VNDA

ZAPP

Why Jabil Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

movers image

ADBE

BAND

BIMI

CABA

CANF

CNSP

CORT

FOXO

GANX

INAB

IONM

IRON

JFBR

KITT

KYTX

LGVN

NAAS

NVAX

ONMD

PENN

POWW

RARE

RNXT

RZLT

THMO

TWOU

WLFC

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Cute,Little,Girl,Lying,In,Hospital,Bed,With,Teddy,Bear

Biotech

General

NanoViricides (NASDAQ: NNVC) Hits Key Milestones For Its Virus-Fighting Drug Candidate NV-387 In 2023; More To Come This Year

Nanoviricides Inc

Press Releases

NanoViricides, Inc. Has Filed its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial -  Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

Events

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

NanoViricides Engages CRO for Phase II Clinical Trial

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

Earnings

NanoViricides, Inc. Has Filed its Quarterly Report

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

Abpro Hldgs

ABVC BioPharma

Allakos

BioAtla

BioVie

Bolt Biotherapeutics, Inc. - Common Stock

Bolt Biotherapeutics

Carisma Therapeutics, Inc. - Common Stock

CARISMA Therapeutics

Cardio Diagnostics Holdings Inc. - Common stock

Cardio Diagnostics Hldgs

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Cellectar Biosciences, Inc. - Common Stock

Cellectar Biosciences

Curis

CEL-SCI

Cyclo Therapeutics

GlycoMimetics

IN8bio

Longeveron

Leap Therapeutics

Lisata Therapeutics

MEI Pharma

NextCure

Palatin Techs

Q32 Bio

Senti Biosciences

TC BioPharm (Holdings) plc - American Depositary Shares

TC BioPharm (Holdings)

Tenax Therapeutics

EF Hutton

Comments

Nanoviricides

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga